Literature DB >> 27044944

Mouse Models for Assessing Protein Immunogenicity: Lessons and Challenges.

Wim Jiskoot1, Grzegorz Kijanka1, Theodore W Randolph2, John F Carpenter3, Atanas V Koulov4, Hanns-Christian Mahler4, Marisa K Joubert5, Vibha Jawa6, Linda O Narhi7.   

Abstract

The success of clinical and commercial therapeutic proteins is rapidly increasing, but their potential immunogenicity is an ongoing concern. Most of the studies that have been conducted over the past few years to examine the importance of various product-related attributes (in particular several types of aggregates and particles) and treatment regimen (such as dose, dosing schedule, and route of administration) in the development of unwanted immune responses have utilized one of a variety of mouse models. In this review, we discuss the utility and drawbacks of different mouse models that have been used for this purpose. Moreover, we summarize the lessons these models have taught us and some of the challenges they present. Finally, we provide recommendations for future research utilizing mouse models to improve our understanding of critical factors that may contribute to protein immunogenicity.
Copyright © 2016 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  immunogenicity; in vivo models; protein aggregation

Mesh:

Substances:

Year:  2016        PMID: 27044944      PMCID: PMC4846475          DOI: 10.1016/j.xphs.2016.02.031

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  88 in total

1.  Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors.

Authors:  Theodora Fifis; Anita Gamvrellis; Blessing Crimeen-Irwin; Geoffrey A Pietersz; Jie Li; Patricia L Mottram; Ian F C McKenzie; Magdalena Plebanski
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

2.  Sizing the optimal dimensions of a vaccine delivery system: a particulate matter.

Authors:  Bram Slütter; Wim Jiskoot
Journal:  Expert Opin Drug Deliv       Date:  2015-12-07       Impact factor: 6.648

3.  Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta).

Authors:  L Runkel; W Meier; R B Pepinsky; M Karpusas; A Whitty; K Kimball; M Brickelmaier; C Muldowney; W Jones; S E Goelz
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

4.  Classification and characterization of therapeutic antibody aggregates.

Authors:  Marisa K Joubert; Quanzhou Luo; Yasser Nashed-Samuel; Jette Wypych; Linda O Narhi
Journal:  J Biol Chem       Date:  2011-03-25       Impact factor: 5.157

5.  Biopharmaceutical benchmarks 2014.

Authors:  Gary Walsh
Journal:  Nat Biotechnol       Date:  2014-10       Impact factor: 54.908

6.  Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations.

Authors:  G Shankar; S Arkin; L Cocea; V Devanarayan; S Kirshner; A Kromminga; V Quarmby; S Richards; C K Schneider; M Subramanyam; S Swanson; D Verthelyi; S Yim
Journal:  AAPS J       Date:  2014-04-24       Impact factor: 4.009

Review 7.  Overcoming current limitations in humanized mouse research.

Authors:  Michael A Brehm; Leonard D Shultz; Jeremy Luban; Dale L Greiner
Journal:  J Infect Dis       Date:  2013-11       Impact factor: 5.226

8.  Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity.

Authors:  Andreas Seidl; Otmar Hainzl; Marleen Richter; Robert Fischer; Stephan Böhm; Britta Deutel; Martin Hartinger; Jörg Windisch; Nicole Casadevall; Gerard Michel London; Iain Macdougall
Journal:  Pharm Res       Date:  2011-11-18       Impact factor: 4.200

9.  Cytokine stimulation of multilineage hematopoiesis from immature human cells engrafted in SCID mice.

Authors:  T Lapidot; F Pflumio; M Doedens; B Murdoch; D E Williams; J E Dick
Journal:  Science       Date:  1992-02-28       Impact factor: 47.728

10.  Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses.

Authors:  Marisa K Joubert; Martha Hokom; Catherine Eakin; Lei Zhou; Meghana Deshpande; Matthew P Baker; Theresa J Goletz; Bruce A Kerwin; Naren Chirmule; Linda O Narhi; Vibha Jawa
Journal:  J Biol Chem       Date:  2012-05-14       Impact factor: 5.157

View more
  16 in total

1.  Flow Microscopy Imaging Is Sensitive to Characteristics of Subvisible Particles in Peginesatide Formulations Associated With Severe Adverse Reactions.

Authors:  Austin L Daniels; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2018-02-01       Impact factor: 3.534

2.  Immune Suppression During Preclinical Drug Development Mitigates Immunogenicity-Mediated Impact on Therapeutic Exposure.

Authors:  Jonathan Herskovitz; Josiah Ryman; Theingi Thway; Stephanie Lee; Lei Zhou; Narendra Chirmule; Bernd Meibohm; Vibha Jawa
Journal:  AAPS J       Date:  2017-01-09       Impact factor: 4.009

Review 3.  Design and engineering of deimmunized biotherapeutics.

Authors:  Karl E Griswold; Chris Bailey-Kellogg
Journal:  Curr Opin Struct Biol       Date:  2016-06-17       Impact factor: 6.809

4.  How Close Are We to Profiling Immunogenicity Risk Using In Silico Algorithms and In Vitro Methods?: an Industry Perspective.

Authors:  Jochem Gokemeijer; Vibha Jawa; Shibani Mitra-Kaushik
Journal:  AAPS J       Date:  2017-10-02       Impact factor: 4.009

5.  Chemical and Biophysical Characteristics of Monoclonal Antibody Solutions Containing Aggregates Formed during Metal Catalyzed Oxidation.

Authors:  Linda O Narhi; Quanzhou Luo; Jette Wypych; Riccardo Torosantucci; Andrea Hawe; Kiyoshi Fujimori; Yasser Nashed-Samuel; Vibha Jawa; Marisa K Joubert; Wim Jiskoot
Journal:  Pharm Res       Date:  2017-11-06       Impact factor: 4.200

6.  Determination of Critical Quality Attributes for a Biotherapeutic in the QbD Paradigm: GCSF as a Case Study.

Authors:  Sumit K Singh; Deepak Kumar; Anurag S Rathore
Journal:  AAPS J       Date:  2017-09-05       Impact factor: 4.009

7.  A humanized minipig model for the toxicological testing of therapeutic recombinant antibodies.

Authors:  Tatiana Flisikowska; Jerome Egli; Angelika Schnieke; Antonio Iglesias; Krzysztof Flisikowski; Marlene Stumbaum; Erich Küng; Martin Ebeling; Roland Schmucki; Guy Georges; Thomas Singer; Mayuko Kurome; Barbara Kessler; Valeri Zakhartchenko; Eckhard Wolf; Felix Weber
Journal:  Nat Biomed Eng       Date:  2022-09-22       Impact factor: 29.234

8.  Machine learning and statistical analyses for extracting and characterizing "fingerprints" of antibody aggregation at container interfaces from flow microscopy images.

Authors:  Austin L Daniels; Christopher P Calderon; Theodore W Randolph
Journal:  Biotechnol Bioeng       Date:  2020-07-28       Impact factor: 4.530

Review 9.  Antibacterial Peptides in Dermatology-Strategies for Evaluation of Allergic Potential.

Authors:  Milena Deptuła; Anna Wardowska; Maria Dzierżyńska; Sylwia Rodziewicz-Motowidło; Michał Pikuła
Journal:  Molecules       Date:  2018-02-14       Impact factor: 4.411

10.  Measuring Ultra-Weak Protein Self-Association by Non-ideal Sedimentation Velocity.

Authors:  Sumit K Chaturvedi; Vatsala Sagar; Huaying Zhao; Graeme Wistow; Peter Schuck
Journal:  J Am Chem Soc       Date:  2019-02-06       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.